Teva outlines 2030 targets ahead of R&D Day event (TEVA:NYSE)
· seekingalpha.com
Teva Pharmaceutical (TEVA) targets $6B-$7B in innovative medicines revenue by 2030 and projects mid-single-digit revenue growth from 2026 to 2030. Read more here.
Before inaugurating its first-ever R&D Day event, Teva Pharmaceutical Industries (TEVA) on Wednesday laid out plans to generate $6B - $7B in revenue from its in...